Literature DB >> 28341716

Multiparametric Evaluation in Differentiating Glioma Recurrence from Treatment-Induced Necrosis Using Simultaneous 18F-FDG-PET/MRI: A Single-Institution Retrospective Study.

A Jena1, S Taneja2, A Jha2, N K Damesha3, P Negi2, G K Jadhav4, S M Verma4, S K Sogani3.   

Abstract

BACKGROUND AND
PURPOSE: Differentiating glioma recurrence from treatment-induced necrosis can be a challenge on conventional imaging. This study aimed to assess the diagnostic performance of each functional MR imaging and PET parameter derived by using simultaneous FDG-PET/MR imaging individually and in combination in the evaluation of suspected glioma recurrence.
MATERIALS AND METHODS: Thirty-five treated glioma patients with 41 enhancing lesions (World Health Organization grade II = 9, III = 13, IV = 19) on MR imaging after an operation followed by radiation therapy and/or chemotherapy formed part of this study. Using PET/MR imaging, we calculated the normalized mean relative CBV, mean ADC, Cho/Cr, and maximum and mean target-to-background ratios. Statistical analysis was performed to determine the diagnostic performance of each parameter by receiver operating characteristic analysis individually and in combination with multivariate receiver operating characteristic analysis for the detection of glioma recurrence. Histopathology or clinicoradiologic follow-up was considered the criterion standard.
RESULTS: Of 35 patients, 25 (30 lesions) were classified as having a recurrence and 10 (11 lesions) patients as having treatment-induced necrosis. Parameters like rCBVmean (mean relative CBV), ADCmean, Cho/Cr, and maximum and mean target-to-background ratios were statistically significant in the detection of recurrent lesions with an accuracy of 77.5%, 78.0%, 90.9%, 87.8%, and 87.8%, respectively. On multivariate receiver operating characteristic analysis, the combination of all 3 MR imaging parameters resulted in an area under the curve of 0.913 ± 0.053. Furthermore, an area under the curve of 0.935 ± 0.046 was obtained when MR imaging parameters (ADCmean and Cho/Cr) were combined with the PET parameter (mean target-to-background ratio), demonstrating an increase in diagnostic accuracy.
CONCLUSIONS: Simultaneous PET/MR imaging with FDG offers correlative and synergistic multiparametric assessment of glioma recurrence with increased accuracy and clinical utility.
© 2017 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28341716      PMCID: PMC7960371          DOI: 10.3174/ajnr.A5124

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  30 in total

1.  Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects.

Authors:  James R Fink; Robert B Carr; Eiji Matsusue; Ramesh S Iyer; Jason K Rockhill; David R Haynor; Kenneth R Maravilla
Journal:  J Magn Reson Imaging       Date:  2011-10-14       Impact factor: 4.813

2.  Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.

Authors:  S Mong; B M Ellingson; P L Nghiemphu; H J Kim; L Mirsadraei; A Lai; W Yong; T M Zaw; T F Cloughesy; W B Pope
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

3.  Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease.

Authors:  Achim Seeger; Christian Braun; Marco Skardelly; Frank Paulsen; Jens Schittenhelm; Ulrike Ernemann; Sotirios Bisdas
Journal:  Acad Radiol       Date:  2013-12       Impact factor: 3.173

4.  Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.

Authors:  Seymur Gahramanov; Ahmed M Raslan; Leslie L Muldoon; Bronwyn E Hamilton; William D Rooney; Csanad G Varallyay; Jeffrey M Njus; Marianne Haluska; Edward A Neuwelt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-13       Impact factor: 7.038

5.  Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy.

Authors:  June L Chan; Susan W Lee; Benedick A Fraass; Daniel P Normolle; Harry S Greenberg; Larry R Junck; Stephen S Gebarski; Howard M Sandler
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

6.  Diagnostic approach in suspected recurrent primary brain tumors using (18)FDG-PET/MRI, perfusion MRI, visual and quantitative analysis, and three dimensional stereotactic surface projections. First experience in Mexico.

Authors:  G Estrada; L González-Maya; M A Celis-López; J Gavito; J M Lárraga-Gutiérrez; P Salgado; J Altamirano
Journal:  Rev Esp Med Nucl       Date:  2008 Sep-Oct

7.  Clinical applications of hybrid PET/MRI in neuroimaging.

Authors:  Valentina Garibotto; Susanne Heinzer; Serge Vulliemoz; Renaud Guignard; Michael Wissmeyer; Margitta Seeck; Karl-Olof Lovblad; Habib Zaidi; Osman Ratib; Maria-Isabel Vargas
Journal:  Clin Nucl Med       Date:  2013-01       Impact factor: 7.794

8.  Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma.

Authors:  Michael S Enslow; Lauren V Zollinger; Kathryn A Morton; Regan I Butterfield; Dan J Kadrmas; Paul E Christian; Kenneth M Boucher; Marta E Heilbrun; Randy L Jensen; John M Hoffman
Journal:  Clin Nucl Med       Date:  2012-09       Impact factor: 7.794

9.  Detection of glioma recurrence by ¹¹C-methionine positron emission tomography and dynamic susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis.

Authors:  Sheng-Ming Deng; Bin Zhang; Yi-Wei Wu; Wei Zhang; Yin-Yin Chen
Journal:  Nucl Med Commun       Date:  2013-08       Impact factor: 1.690

Review 10.  Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies.

Authors:  Olivier Keunen; Torfinn Taxt; Renate Grüner; Morten Lund-Johansen; Joerg-Christian Tonn; Tina Pavlin; Rolf Bjerkvig; Simone P Niclou; Frits Thorsen
Journal:  Adv Drug Deliv Rev       Date:  2014-07-28       Impact factor: 15.470

View more
  14 in total

1.  Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.

Authors:  J Uthoff; F A De Stefano; K Panzer; B W Darbro; T S Sato; R Khanna; D E Quelle; D K Meyerholz; J Weimer; J C Sieren
Journal:  J Neuroradiol       Date:  2018-06-27       Impact factor: 3.447

Review 2.  Neuro-Oncology Practice Clinical Debate: FDG PET to differentiate glioblastoma recurrence from treatment-related changes.

Authors:  Ephraim E Parent; Derek R Johnson; Tyler Gleason; Javier E Villanueva-Meyer
Journal:  Neurooncol Pract       Date:  2021-05-04

3.  Diagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance perfusion measurements and [18F]FET PET in patients with suspected recurrent anaplastic astrocytoma and glioblastoma.

Authors:  Otto M Henriksen; Adam E Hansen; Aida Muhic; Lisbeth Marner; Karine Madsen; Søren Møller; Benedikte Hasselbalch; Michael J Lundemann; David Scheie; Jane Skjøth-Rasmussen; Hans S Poulsen; Vibeke A Larsen; Henrik B W Larsson; Ian Law
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07-30       Impact factor: 10.057

Review 4.  Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature.

Authors:  N Soni; M Ora; N Mohindra; Y Menda; G Bathla
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-27       Impact factor: 3.825

5.  Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas.

Authors:  Julia Cluceru; Sarah J Nelson; Qiuting Wen; Joanna J Phillips; Anny Shai; Annette M Molinaro; Paula Alcaide-Leon; Marram P Olson; Devika Nair; Marisa LaFontaine; Pranathi Chunduru; Javier E Villanueva-Meyer; Soonmee Cha; Susan M Chang; Mitchel S Berger; Janine M Lupo
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 13.029

6.  Differentiation of Treatment-Related Effects from Glioma Recurrence Using Machine Learning Classifiers Based Upon Pre-and Post-Contrast T1WI and T2 FLAIR Subtraction Features: A Two-Center Study.

Authors:  Xin-Yi Gao; Yi-Da Wang; Shi-Man Wu; Wen-Ting Rui; De-Ning Ma; Yi Duan; An-Ni Zhang; Zhen-Wei Yao; Guang Yang; Yan-Ping Yu
Journal:  Cancer Manag Res       Date:  2020-05-07       Impact factor: 3.989

Review 7.  Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.

Authors:  Anastasia Zikou; Chrissa Sioka; George A Alexiou; Andreas Fotopoulos; Spyridon Voulgaris; Maria I Argyropoulou
Journal:  Contrast Media Mol Imaging       Date:  2018-12-02       Impact factor: 3.161

8.  Radiological diagnosis of brain radiation necrosis after cranial irradiation for brain tumor: a systematic review.

Authors:  Motomasa Furuse; Naosuke Nonoguchi; Kei Yamada; Tohru Shiga; Jean-Damien Combes; Naokado Ikeda; Shinji Kawabata; Toshihiko Kuroiwa; Shin-Ichi Miyatake
Journal:  Radiat Oncol       Date:  2019-02-06       Impact factor: 3.481

9.  Individualized discrimination of tumor recurrence from radiation necrosis in glioma patients using an integrated radiomics-based model.

Authors:  Kai Wang; Zhen Qiao; Xiaobin Zhao; Xiaotong Li; Xin Wang; Tingfan Wu; Zhongwei Chen; Di Fan; Qian Chen; Lin Ai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-26       Impact factor: 9.236

10.  Dual-energy spectral CT quantitative parameters for the differentiation of Glioma recurrence from treatment-related changes: a preliminary study.

Authors:  Yanchun Lv; Jian Zhou; Xiaofei Lv; Li Tian; Haoqiang He; Zhigang Liu; Yi Wu; Lujun Han; Meili Sun; Yadi Yang; Chengcheng Guo; Cong Li; Rong Zhang; Chuanmiao Xie; Yinsheng Chen; Zhongping Chen
Journal:  BMC Med Imaging       Date:  2020-01-16       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.